{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:08:14Z","timestamp":1763104094229},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Some conventional laboratory tests are routinely used for the prediction of systemic autoimmune disease activity, such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP); however, they can give false-negative results, pointing out the need to identify more specific markers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We evaluated biomarkers in 21 Italian patients na\u00efve to treatment with a diagnosis of autoimmune rheumatic disease according to the 2010 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis during 6 months of therapeutic treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found a significant difference in interleukin-6 (IL-6), CRP, ESR, platelet count, and fecal calprotectin in diagnosed patients compared with healthy participants and a significant decrease in these values during follow-up, except for IL-6 and platelet count.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We found that CRP, ESR, and fecal calprotectin seemed to be related to autoimmune rheumatic disorders and to be associated with therapy, whereas serum calprotectin and IL-6 did not seem to be associated with disease improvement after the start of treatment, along with leukocyte count and platelet count.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmab034","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T04:18:09Z","timestamp":1616559489000},"page":"123-127","source":"Crossref","is-referenced-by-count":3,"title":["Interleukin-6 and Serum\/Fecal Calprotectin as Useful Specific Markers for Monitoring Rheumatic Diseases: A Pilot Study"],"prefix":"10.1093","volume":"53","author":[{"given":"Margherita","family":"Scapaticci","sequence":"first","affiliation":[{"name":"Unified Metropolitan Laboratory, AUSL Bologna , Bologna , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Bartolini","sequence":"additional","affiliation":[{"name":"Unified Metropolitan Laboratory, AUSL Bologna , Bologna , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Biscaro","sequence":"additional","affiliation":[{"name":"Rheumatology Department, San Camillo Hospital , Treviso , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzo","family":"Biscaro","sequence":"additional","affiliation":[{"name":"Rheumatology Department, San Camillo Hospital , Treviso , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Da Rin","sequence":"additional","affiliation":[{"name":"Laboratory Medicine, IRCCS Policlinico San Martino Hospital , Genova , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"2023020416002225200_CIT0001","author":"Clunie G, Wilkinson N, Nikiphorou E, et al."},{"issue":"10055","key":"2023020416002225200_CIT0002","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet."},{"issue":"3","key":"2023020416002225200_CIT0003","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.semarthrit.2017.04.007","article-title":"Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: a prospective study with 12 months follow-up","volume":"47","author":"Ram\u00edrez","year":"2017","journal-title":"Semin Arthritis Rheum."},{"key":"2023020416002225200_CIT0004","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art view","volume":"1","author":"Coatels","year":"2017","journal-title":"Clin Med."},{"key":"2023020416002225200_CIT0005","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Longo","year":"2017","journal-title":"N Engl J Med."},{"key":"2023020416002225200_CIT0006"},{"issue":"4","key":"2023020416002225200_CIT0007","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrrheum.2018.38","article-title":"The non-haemostatic role of platelets in systemic lupus erythematosus","volume":"14","author":"Linge","year":"2018","journal-title":"Nat Rev Rheumatol."},{"issue":"4","key":"2023020416002225200_CIT0008","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00124743-199608000-00007","article-title":"Leukocytosis in rheumatoid arthritis","volume":"2","author":"Syed","year":"1996","journal-title":"J Clin Rheumatol."},{"key":"2023020416002225200_CIT0009","article-title":"Hematological manifestations among patients with rheumatic diseases","author":"Kleina","year":"2020","journal-title":"Acta Haematol."},{"issue":"7","key":"2023020416002225200_CIT0010","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3899\/jrheum.080770","article-title":"Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%\u201345% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States","volume":"36","author":"Sokka","year":"2009","journal-title":"J Rheumatol."},{"key":"2023020416002225200_CIT0011","first-page":"S-23","article-title":"An evidence-based approach to laboratory tests in usual care of patients with rheumatoid arthritis","volume":"32","author":"Pincus","year":"2014","journal-title":"Clin Exp Rheumatol."},{"issue":"1\u20132","key":"2023020416002225200_CIT0012","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/00365513.2017.1413591","article-title":"Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate","volume":"78","author":"Nielsen","year":"2018","journal-title":"Scand J Clin Lab Invest."},{"issue":"12","key":"2023020416002225200_CIT0013","first-page":"2523","article-title":"Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8\/14 heterodimer in rheumatoid arthritis synovial membrane","volume":"26","author":"Youssef","year":"1999","journal-title":"J Rheumatol."},{"issue":"5","key":"2023020416002225200_CIT0014","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3899\/jrheum.140628","article-title":"Calprotectin as a biomarker for rheumatoid arthritis: a systematic review","volume":"42","author":"Abildtrup","year":"2015","journal-title":"J Rheumatol."},{"issue":"12","key":"2023020416002225200_CIT0015","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1136\/annrheumdis-2017-211695","article-title":"Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis","volume":"76","author":"Jonsson","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"2023020416002225200_CIT0016","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2013-203923","article-title":"MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis","volume":"74","author":"Choi","year":"2015","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"2023020416002225200_CIT0017","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3349\/ymj.2011.52.1.113","article-title":"The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients","volume":"52","author":"Chung","year":"2011","journal-title":"Yonsei Med J."},{"key":"2023020416002225200_CIT0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejr.2012.11.002","article-title":"Clinical significance of serum interleukin-6 and \u2013174 G\/C promoter polymorphism in rheumatoid arthritis patients","volume":"35","author":"Gaber","year":"2013","journal-title":"Egypt Rheumatol"},{"issue":"6","key":"2023020416002225200_CIT0019","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/1744666X.2017.1295850","article-title":"The role and therapeutic targeting of IL-6 in rheumatoid arthritis","volume":"13","author":"Narazaki","year":"2017","journal-title":"Expert Rev Clin Immunol."},{"key":"2023020416002225200_CIT0020","first-page":"1124","article-title":"Rheumatoid arthritis: previously untreated early disease","volume":"8","author":"Gunasekera","year":"2016","journal-title":"BMJ Clin Evid"},{"issue":"3","key":"2023020416002225200_CIT0021","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/ard.2003.010298","article-title":"Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis","volume":"63","author":"van Aken","year":"2004","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"2023020416002225200_CIT0022","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/annrheumdis-2013-205143","article-title":"Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial","volume":"74","author":"ter Wee","year":"2015","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"2023020416002225200_CIT0023","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/rheumatology\/kex223","article-title":"Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial","volume":"56","author":"Konijn","year":"2017","journal-title":"Rheumatology (Oxford)."},{"key":"2023020416002225200_CIT0024","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smole","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"2023020416002225200_CIT0025","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"1","key":"2023020416002225200_CIT0026","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum."},{"issue":"1","key":"2023020416002225200_CIT0027","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.gpb.2015.11.004","article-title":"EDISON-WMW: Exact Dynamic Programing Solution of the Wilcoxon-Mann-Whitney test","volume":"14","author":"Marx","year":"2016","journal-title":"Genomics Proteomics Bioinformatics."},{"issue":"1","key":"2023020416002225200_CIT0028","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.1780350105","article-title":"Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis","volume":"35","author":"van der Heijde","year":"1992","journal-title":"Arthritis Rheum."},{"issue":"8","key":"2023020416002225200_CIT0029","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s10067-018-4091-5","article-title":"Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein","volume":"37","author":"Hurnakova","year":"2018","journal-title":"Clin Rheumatol."},{"issue":"3","key":"2023020416002225200_CIT0030","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"1","key":"2023020416002225200_CIT0031","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1515\/cclm-2019-0508","article-title":"Pre-analytical and analytical confounders of serum calprotectin as a biomarker in rheumatoid arthritis","volume":"58","author":"Van Hoovels","year":"2019","journal-title":"Clin Chem Lab Med."},{"issue":"4","key":"2023020416002225200_CIT0032","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1515\/cclm-2016-0522","article-title":"Fecal calprotectin in inflammatory bowel diseases: update and perspectives","volume":"55","author":"Manceau","year":"2017","journal-title":"Clin Chem Lab Med."},{"issue":"1","key":"2023020416002225200_CIT0033","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ajg.2009.545","article-title":"Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn\u2019s Disease (SES-CD) than CRP, blood leukocytes, and the CDAI","volume":"105","author":"Schoepfer","year":"2010","journal-title":"Am J Gastroenterol."},{"issue":"2","key":"2023020416002225200_CIT0034","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bjd.17745","article-title":"Evaluation of subclinical gut inflammation using faecal calprotectin levels and colonic mucosal biopsy in patients with psoriasis and psoriatic arthritis","volume":"181","author":"Adarsh","year":"2019","journal-title":"Br J Dermatol."},{"key":"2023020416002225200_CIT0035","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1590\/1807-3107BOR-2016.vol30.0051","article-title":"The effect of smoking on myeloid-related protein-8 and myeloid-related protein-14","volume":"30","author":"Ertugrul","year":"2016","journal-title":"Braz Oral Res"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/53\/2\/123\/49091107\/lmab034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/53\/2\/123\/49091107\/lmab034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T16:00:50Z","timestamp":1675526450000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/53\/2\/123\/6354052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,8,18]]},"published-print":{"date-parts":[[2022,3,7]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmab034","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,8,18]]}}}